Article Versions Notes

Sezer Z, Pavel STI, Inal A, Yetiskin H, Kaplan B, Uygut MA, Aslan AF, Bayram A, Mazicioglu M, Kalin Unuvar G, et al. Long-Term Immunogenicity and Safety of a Homologous Third Dose Booster Vaccination with TURKOVAC: Phase 2 Clinical Study Findings with 32-Week Post-Booster Follow-Up. Vaccines. 2024; 12(2):140. https://doi.org/10.3390/vaccines12020140

Sezer, Zafer, Shaikh Terkis Islam Pavel, Ahmet Inal, Hazel Yetiskin, Busra Kaplan, Muhammet Ali Uygut, Ahmet Furkan Aslan, Adnan Bayram, Mumtaz Mazicioglu, Gamze Kalin Unuvar, and et al. 2024. "Long-Term Immunogenicity and Safety of a Homologous Third Dose Booster Vaccination with TURKOVAC: Phase 2 Clinical Study Findings with 32-Week Post-Booster Follow-Up" Vaccines 12, no. 2: 140. https://doi.org/10.3390/vaccines12020140

Sezer, Z., Pavel, S. T. I., Inal, A., Yetiskin, H., Kaplan, B., Uygut, M. A., Aslan, A. F., Bayram, A., Mazicioglu, M., Kalin Unuvar, G., Yuce, Z. T., Aydin, G., Kaya, R. K., Ates, I., Kara, A., & Ozdarendeli, A. (2024). Long-Term Immunogenicity and Safety of a Homologous Third Dose Booster Vaccination with TURKOVAC: Phase 2 Clinical Study Findings with 32-Week Post-Booster Follow-Up. Vaccines, 12(2), 140. https://doi.org/10.3390/vaccines12020140